Planet. I'm uh my name is Tim Tobin. I'm the uh CEO of Planet. Uh Planet was it's a little bit different journey than probably most of the companies you have heard from. Planet started out as part of a semiconductor technology company. So semiconductor making chips. You make chips on wafers. Um and it was part of a company that I was uh co-founder and CEO of. We started in '98. um we accessed it in 2023 uh to a public company but but uh what we were doing is we were developing one of the processes that you use to make a chip um and it's a process where we polish the surface of the of the wafer where chips are made such that it's almost perfectly atomically smooth and and we are doing it for bigname companies like Intel and Samsung and Facebook and and companies like that. So um our CFO one day said to us you know here we are this small 2530 million company where else can we use this technology and we said that's a great question. So we started looking for it. um so again that's where where planets came from out of the semiconductor uh industry. So what is planets? I'm going to define what it is and a couple things that it's not. We are we are not a product company. So we are an IP company. We took technology from one industry we moved it to another one. Um, we have a a patented technology platform that we adapted from semiconductor manufacturing and then we license it to industry leaders so they can create the most advanced surgical instruments in the world, surgical cutting instruments in the world. So, [clears throat] most people don't know much about semiconductor manufacturing. So, just to put it in perspective real quick, it's the most advanced complicated uh process in the world make making chips. um to to date now if you look at a chip the size of your fingernail we're putting 50 billion transistors in that tiny little space which is remarkable when you think about it. So the scale that we're doing that on is very complex. So to give you an idea when we talk about polishing the the kind of scale um we are taking semiconductor level precision and putting it into the surgical instruments. So we're not putting chips in here. Um, this is kind of what AI gave me when I said fuse, semiconductor, and and medical. But, um, we take the same precision that we needed to to make a a chip, which is we polish the surface of the surgical instruments now such that it's the same as if you took a hair out of your head. You look at the little round end of that. You cut that up 15,000 times and you take one piece. So, that's the level of precision we're now putting into surgeons hands to be able to do or robots hands to be able to do much more effective surgery. So current um you may be shocked surgeons are even shocked when we show them every u medical grade stainless steel surgical device is manufactured by taking that stainless steel and grinding it with diamond grit wheels. So if you look at it under magnification um here is a side profile of what's doing the cutting and see this little edge right here with all the jagged serrations on it. That's actually the blade that's doing the cutting which is remarkable when you look at that. Looks like a medieval torture device, right? So, and by the way, so this one's a scalpel blade, but every instrument cutting looks the same. If it's scissors, you just have two of those going against each other. Endo cutters, all sorts of different things. >> um, so is there a problem with that? That's the question. So, let let me show you the problem. The problem is you get with 100-year technology, um, and this, by the way, is the number one blade in the entire world. We didn't look for the worst one. So, everything else looks worse than that. So, with a 100-y old technology, you get both clinical and economic constraints, which I'll get into in a minute of that. And you can see it. It's really intuitive when when you think about this. So, if you have a blade that looks like a a jagged serrated saw, it tears and rips the tissues out and does much more trauma damage than it actually needs to do. So, we buy the blade looking like this. We apply our polish to it. It looks like this. And of course the resultant is a much lower trauma, much lower inflammation incision that you get. All of this ripping and tag snagging and tearing doesn't have to be healed anymore. So if you do less damage to begin with, you don't have to to uh uh many of the complications. Okay. So for the the market for this again, we're we are an IP a manufacturing technology that we will put into our customers our licenses line. Um, if you look at the roughly 15 billion dollar surgical cutting instrument market, um, we've carved it down to four really where our technology could apply, um, it's 8.4 billion market for our our customers and we've carved it up into four different pieces here. Um, the robotic MIS, which which I'm going to go into in more depth because there's if you look at the economic value to that one, that one is the most compelling case that that we have as well as traditional open ortho and reprocessing repair. So we are now at we just started in April speaking with uh uh many of these companies up here about licensing it. So we're just starting that process and we have names that you would recognize what you do up there in every single one of those four that we were talking to about licensing and particular interest within the robotics. So from a clinical standpoint, this is kind of the minimum bar to entry, but as we talked about before, it doesn't take a whole lot of um you don't have to be a medical professional to understand that one gives you a much better cut than the other one. So, what does it do? We get much uh much lower inflammation. Um 50 to 60% less collagen deposition. Here's this little red line right around here. That's the collagen deposition. And you can see that that's significantly lower from a planet blade. That's 7 days after incision. Um you also get much faster recovery. Um so this is after 3 days sidebyside incisions. 90% wound closure with the planet blade and 10 only 10% wound closure from a traditional cutting blade. And again, this applies to whether it's scissors, ronjours, curettes, you you name it and anything that's cutting. So that leads to much uh much reduced post-operative complications. Um I'm going to cite just two of them here because usually I can take too much time and and go through my whole you know my whole nine minutes in this one one slide. Um but we have adverse scarring. If you're familiar with kloids or hypertrophic scarring, um they're a big problem. The darker your skin tone is, the more prone you are to those. Um we have a three-year 114 patient study uh coming out. Matter of fact, uh it's about to be published in the PRS. 86% reduction by just changing the blade. So the other one is a diabetic wound healing. Um [snorts] we had uh a study done with diabetic uh a diabetic patient set and a non-diabetic uh p healthy set um healthy with the conventional blade and ours with the planet. In all three healing phases uh the planet blade was equivalent or better and in most cases better than a conventional blade on a healthy healthy patient. So um and if you're familiar at all with diabetic foot ulcers uh you know diabetes obviously a big problem. 25% of the people that have a diabetic foot ulcer um will excuse me 25% of diabetics will get a diabetic foot ulcer and then once you have one it's the same five-year mortality as all-c causeed cancer. So if you get much better healing by using our instruments you'll get much better chance of survival there. The [clears throat] big thing why why do our OEM partners want to license this? The big thing is it brings differentiation. Everybody has been competing with that same jagged technology that we showed you before. So what's the big differentiation? Of course, there's a clinical that I spoke about and there's an efficiency, but really what it brings is the durability. So all those serrations that rip and tear and snag the tissue out, that's also the failure mechanism of all those devices. So they either gunk up with tissue and then they are no longer sharp anymore or they bend over and break off. So we get rid of those for the clinical benefits and there's tremendous durability, two to five times longer. So then you know customers in those buckets that we we talked about or licenses they can decide to compete on margin or market share. They can truly differentiate from the people that are there other than them. So I mentioned uh the uh robotic surgery. Here's where it really is um a very compelling story um [snorts] from an economic standpoint as well as as well as the clinical. Um for those of you are familiar with uh the soft tissue robotic surgery business model um it's driven by instrumentation. It's kind of the razor razor blade model that we heard heard earlier. Um, if you look at intuitive, and I'm not picking on intuitive, but their numbers are public, so we could get them right. 60 61% of their revenue last year was from instrumentation and accessories. The robots were less than 20 20%. So, the way they sell their their instruments like the monopolar curve scissors here is that they're sold as a limited life reusable. Um, in this particular case, so uh the monopolar curve scissors are guaranteed for 10 uses. They never make 10 uses. They usually make somewhere between six and eight and then either hospitals throw them away if they're kind of lazy or sometimes they send them in for credit by putting on our technology. So it's a predominant universally acknowledged by all these are all soft tissue companies over here. There's not one we've spoken with yet that hasn't said this is either the major problem or one of my top three problems that I'm dealing with. So every single one and we're a small company. We haven't gone and talked to all of them, but there's uh six or seven of the companies and the big ones that you would anticipate that we've spoken with that that all acknowledge this is a big big problem, right? And a predominant customer complaint. When we put our technology onto the monopolar curve scissors, they no longer they'll get that full 10 use. You can then repolish them again coming back and you will get an in our testing, we get 12 to 14 more uses. So, and you know that you don't have the cost of goods sold, the price can drop for the hospital. There's so many good things that come out of that from an economic standpoint because of that durability. So, [clears throat and cough] uh lastly, yeah, I usually put in here a slide, you know, the team and the the investment. We have um the the parent company was the incubator. Again, we've raised about uh so it funded all that. We've raised $8.5 million out of a $10 million series A. So, we have a little bit left. Um, largely what we're doing with that is, you know, it's been friends and family, a few surgeons, the management team's in for almost half of that. So, we're we are still looking for maybe a strategic investor, but otherwise we'll we'll do that ourselves. So, we we like to say we don't invent surgical instruments, but we perfect them. And it brings you the first innovative cutting uh differentiation in over a hundred years. That original blade I showed you was patented in 1915. Nothing has changed since then. So, major clinical and economic benefits for the stakeholders. Uh it's patented. Matter of fact, we got our big broad patent was granted earlier this year. So it's patented to 2043. Um and then it continues to grow the value proposition for our o OEM partners which is is fantastic. Right. So and ultimately brings phenomenal unparalleled healing That's it.